Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Women with ovarian cancer who:
Patients will be excluded if:
Questions about the study should be directed to Clovis Oncology Clinical Trial Navigation Service at: 1-855-262-3040 or by email
The study is open and recruiting at sites in these state: AZ, CA, CO, FL, ME, MI, NY, OH and these countries: Canada, Czechia, Brazil, Hungary, Israel, Italy, Poland, Spain, Ukraine, United Kingdom
ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens. Visit the ARIEL4 Study page for more information.
ARIEL4 is a randomized, 2-arm, open-label cross-over study.
This is a randomized study, which means that participants will be placed into one of the two treatment groups by chance. Neither patients nor the research doctor will choose the group participants are placed in. This is a 2:1 randomized study. This means that patients will have a slightly greater chance of being placed in the treatment group than the standard treatment group.
The study has two arms. This means that patients in the study are placed in one of two different groups. One group will received the PARP inhibitor rucaparib and the other group will receive one of several standard chemotherapy treatment options chosen by their oncologist.
The study is open-label. All participating patients will know which group they have been assigned to.
The study allows crossover. This means that patients who progress on the standard treatment arm will be given the opportunity to crossover into the rucaparib arm if they choose.
Patients chosen to be on the chemotherapy arm will receive one of several standard of care chemotherapy options as chosen by their doctor.
Patient who qualify for the ARIEL4 trial and enroll, receive the following as part of the study: standard-of-care and study related clinical exams, blood tests, imaging scans of your cancer, lab test results including BRCA and the other biomarker tests, the study medication (rucaparib or chemotherapy) and other assessments. Patients who were treated with chemotherapy on the main study and then experience a worsening of their ovarian cancer may be eligible to receive rucaparib after they discontinue chemotherapy.
Study sites are open in several states in the US and international sites are open as well. For an up-to-date list of study sites, visit the ARIEL4 website.
Monterey, Pacific Cancer Care
Contact: Leslie Hohenbrink (Study Coordinator) by phone: 1-831-375-4105 or by email
Orange, University of California Irvine Health Chao Family Comprehensive Cancer Center
Contact: Anita Wallick (Study Coordinator) by phone: 1-714-456-6191 or by email
Littleton, Rocky Mountain Cancer Centers
Contact: Valerie Apodaca by phone: 1-303-285-5081 or by email
Orlando, Florida Hospital Cancer Institute
Contact: Jane LeBlanc (Study Coordinator) by phone: 1-407-303-2090, ext: 1104286 or by email
Scarborough, ME. Maine Medical Center Maine Medical Partners Gynecologic Oncology
Contact: Robin Donovan (Study Coordinator) by phone: 1-207-396-7089 or by email
Detroit, MI. Wayne State University
Contact: Allison Wolgast (Study Coordinator) by phone: 1-313-576-8994 or by email
Mineola, Women's Contemporary Care Associates (WCCA) – Mineola
Contact: Jennifer Brown (Study Coordinator) by phone: 1-516-663-3115 or by email
Cincinnati, University of Cincinnati
Contact: Lisa Woeste (Study Coordinator) by phone: 1-513-584-4528 or by email
International Study Sites:
Canada, Czechia, Brazil, Hungary, Israel, Italy, Poland, Spain, Ukraine, United Kingdom